<DOC>
	<DOC>NCT00494871</DOC>
	<brief_summary>This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).</brief_summary>
	<brief_title>Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description>Within the US 'Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.' is sponsor.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>20 years or older Japanese male or female Non valvular atrial fibrillation documented by ECG Patients with a risk of stroke and nonCNS systemic embolism Significant mitral stenosis Patients in whom anticoagulants are contraindicated</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>BAY59-7939</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-Valvular Atrial Fibrillation</keyword>
	<keyword>Japanese Patients</keyword>
	<keyword>Phase III</keyword>
	<keyword>12620</keyword>
</DOC>